[vaccinenewsdaily.com] A study funded by GlaxoSmithKline and the PATH Malaria Vaccine Initiative in Maryland has found that Glaxo's experimental malaria vaccine Mosquirix can cut the risk of malaria by 46 percent up to 15 months after the shot. A December 2008 study found similar results, with malaria in infected children reduced by 53 percent eight months after administering the vaccine. The results are encouraging and may lead to one of the first effective malaria vaccine shots, Bloomberg reports.

"We've never had a malaria vaccine get this far in its development and continue to show such promise," Robert Newman, director of the World Health Organization's Global Malaria Program said during a telephone interview, according to Bloomberg. "It's promising and encouraging."

leer la noticia click aqui [+]